| Authors: |
Sadagopan A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Carson M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Zamurs EJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Srikonda S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Weiss CN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA., Bond MJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA., Sodhi A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Donovan KA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Ryan JK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Viswanathan SR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gibson WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. |
